Potential role of tigecycline in the treatment of community-acquired bacterial pneumonia

Figures & data

Table 1 In vitro activity of tigecycline against common CABP respiratory pathogens^a

Bacteria	No. of isolates	MIC90	MIC range (in mg/L)	References
Typical pathogens
S. pneumoniae	6456	0.06	≤0.008–1	^Citation95
S. pneumoniae, penicillin-intermediate susceptible	1077^b	0.06	NR	^Citation36
S. pneumoniae, penicillin resistant	891	0.06	≤0.008–0.25	^Citation95
H. influenzae	6070	0.5	≤0.008–2	^Citation95
H. influenzae, β-lactamase positive	1346	0.5	≤0.008–2	^Citation95
Klebsiella pneumoniae	10,644	2	≤0.008–16	^Citation95
Moraxella catarrhalis	2314	0.5	≤0.06–4	^Citation43
Atypical pathogens
Chlamydia pneumoniae	10	0.125	0.125–0.25	^Citation51
Legionella spp^c	100	8	0.5–8	^Citation52,Citation53
Mycoplasma pneumoniae	30	0.25	0.06–0.25	^Citation50

Notes:

a According to the Clinical Laboratory Standards Institute (CLSI), the MICs considered susceptible are as follows: S. pneumoniae ≤ 0.06 mg/L, H. influenzae ≤0.25 mg/L, and Enterobacteraciae ≤ 2 mg/L;

b Data from North American isolates;

c Isolates (n = 50) of Legionella pneumophilia are represented.

Abbreviations: CABP, community-acquired bacterial pneumonia; MIC, minimum inhibitory concentration; NR, not reported; S. pneumoniae, Streptococcus pneumoniae; H. influenzae, Haemophilus influenzae.

GarrisonMWMuttersRDowzickyMJIn vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007Diagn Microbiol Infect Dis200965328829919733459

 PubMed Web of Science ®Google Scholar

DarabiAHocquetDDowzickyMJAntimicrobial activity against Streptococcus pneumoniae and Haemophilus influenzae collected globally between 2004 and 2008 as part of the Tigecycline Evaluation and Surveillance TrialDiagn Microbiol Infect Dis2010671788620385351

 PubMed Web of Science ®Google Scholar

ZhanelGGPalatnickLNicholKALowDEHobanDJCROSS Study GroupAntimicrobial resistance in Haemophilus influenzae and Moraxella catarrhalis respiratory tract isolates: results of the Canadian Respiratory Organism Susceptibility Study, 1997 to 2002Antimicrob Agents Chemother20034761875188112760861

 PubMed Web of Science ®Google Scholar

RoblinPMHammerschlagMRIn vitro activity of GAR-936 against Chlamydia pneumoniae and Chlamydia trachomatisInt J Antimicrob Agents2000161616311185415

 PubMed Web of Science ®Google Scholar

Wyeth PharmaceuticalsResponse Letter for Tigecycline Inquiry Regarding Legionella pneumophilia in vitro Data (Data on File)Philadelphia (PA)Wyeth Pharmaceuticals2010

 Google Scholar

EdelsteinPHWeissWJEdelsteinMAActivities of tigecycline (GAR-936) against Legionella pneumophila in vitro and in guinea pigs with L. pneumophila pneumoniaAntimicrob Agents Chemother200347253354012543655

 PubMed Web of Science ®Google Scholar

KennyGECartwrightFDSusceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolonesAntimicrob Agents Chemother20014592604260811502536

 PubMed Web of Science ®Google Scholar